Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/β-Catenin/Tcf signaling pathway in human glioblastoma cells

Neurochemical Research

Volumn 38, Issue 11, 2013, Pages 2313-2322

  Sareddy, Gangadhara Reddy ^a   Kesanakurti, Divya ^a   Kirti, Puligurtha Bharadhwaja ^a   Babu, Phanithi Prakash ^a  

^a UNIVERSITY OF HYDERABAD   (India)

Author keywords

Catenin; Celecoxib; Diclofenac; Glioblastoma; NSAIDs; Wnt

Indexed keywords

AXIN; AXIN2; BETA CATENIN; CELECOXIB; CYCLIN D1; DICLOFENAC; GLYCOGEN SYNTHASE KINASE 3BETA; MYC PROTEIN; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG EFFICACY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE TARGETING; GENE TRANSLOCATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR CELL LINE; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA CATENIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DICLOFENAC; GLIOBLASTOMA; HUMANS; PYRAZOLES; SULFONAMIDES; TCF TRANSCRIPTION FACTORS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84885957673     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-013-1142-9     Document Type: Article

References (42)

1. Cha YI, DuBois RN (2007) NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 58:239-252
2. Ulrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6:130-140
3. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252-266
4. Howe LR, Dannenberg AJ (2002) A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol 29:111-119
5. Gupta RA, Dubois RN (1998) Aspirin, NSAIDS, and colon cancer prevention: mechanisms? Gastroenterology 114:1095-1098
6. Smith ML, Hawcroft G, Hull MA (2000) The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 36:664-674
7. Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase- independent actions of cyclooxygenase inhibitors. FASEB J 15:2057-2072
8. Singh R, Cadeddu RP, Fröbel J, Wilk CM, Bruns I, Zerbini LF, Prenzel T, Hartwig S, Brunnert D, Schroeder T, Lehr S, Haas R, Czibere A (2011) The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway. Apoptosis 16:889-901
9. Mayorek N, Naftali-Shani N, Grunewald M (2010) Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity. PLoS ONE 5(9):e12715
10. Xia JJ, Pei LB, Zhuang JP, Ji Y, Xu GP, Zhang ZP, Li N, Yan JL (2010) Celecoxib inhibits β-catenin-dependent survival of the human osteosarcoma MG-63 cell line. J Int Med Res 38:1294-1304
11. McDonald SL, Silver AR (2011) On target? Strategies and progress in the development of therapies for colorectal cancer targeted against WNT signalling. Colorectal Dis 13:360-369
12. Dihlmann S, Siermann A, von Knebel Doeberitz M (2001) The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate β-catenin/Tcf4 signaling. Oncogene 20:645-653
13. Gardner SH, Hawcroft G, Hull MA (2004) Effect of nonsteroidal anti-inflammatory drugs on β-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br J Cancer 91:153-163
14. Bos CL, Kodach LL, van den Brink GR, Diks SH, van Santen MM, Richel DJ, Peppelenbosch MP, Hardwick JCH (2006) Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene 25:6447-6456
15. Boon EMJ, Keller JJ, Wormhoudt TAM, Giardiello FM, Offerhaus GJA, van der Neut R, Pals ST (2004) Sulindac targets nuclear beta-catenin accumulation and Wnt signaling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 90:224-229
16. Yao H, Ashihara E, Maekawa T (2011) Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin Ther Targets 15:873-887
17. Saito-Diaz K, Chen TW, Wang X, Thorne CA, Wallace HA, Page-McCaw A, Lee E (2013) The way Wnt works: components and mechanism. Growth Factors 31:1-31
18. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396-401
19. Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100:2235-2241
20. Sareddy GR, Panigrahi M, Challa S, Mahadevan A, Babu PP (2009a) Activation of Wnt/beta-catenin/Tcf signaling pathway in human astrocytomas. Neurochem Int 55:307-317
21. Sareddy GR, Geeviman K, Panigrahi M, Challa S, Mahadevan A, Babu PP (2012) Increased β-catenin/Tcf signaling in pilocytic astrocytomas: a comparative study to distinguish pilocytic astrocytomas from low-grade diffuse astrocytomas. Neurochem Res 37:96-104
22. Sareddy GR, Challa S, Panigrahi M, Babu PP (2009) Wnt/beta-catenin/Tcf signaling pathway activation in malignant progression of rat gliomas induced by transplacental N-ethyl-N-nitrosourea exposure. Neurochem Res 34:1278-1288
23. Pu P, Zhang Z, Kang C, Jiang R, Jia Z, Wang G, Jiang H (2009) Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther 16:351-361
24. Sareddy GR, Nair BC, Gonugunta VK, Zhang QG, Brenner A, Brann DW, Tekmal RR, Vadlamudi RK (2012) Therapeutic significance of estrogen receptor β agonists in gliomas. Mol Cancer Ther 11:1174-1182
25. Kesanakurti D, Sareddy GR, Babu PP, Kirti PB (2009) Mustard NPR1, a mammalian IkappaB homologue inhibits NF-kappaB activation in human GBM cell lines. Biochem Biophys Res Commun 390:427-433
26. Dihlmann S, Klein S, Doeberitz Mv MK (2003) Reduction of beta-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated beta-catenin. Mol Cancer Ther 2:509-516
27. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31-41
28. Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT (2010) Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 28:2952-2957
29. Ferris JS, McCoy L, Neugut AI, Wrensch M, Lai R (2012) HMG CoA reductase inhibitors, NSAIDs and risk of glioma. Int J Cancer 131:E1031-E1037
30. Scheurer ME, El-Zein R, Thompson PA, Aldape KD, Levin VA, Gilbert MR, Weinberg JS, Bondy ML (2008) Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev 17:1277-1281
31. Sivak-Sears NR, Schwartzbaum JA, Miike R, Moghadassi M, Wrensch M (2004) Case-control study of use of nonsteroidal anti-inflammatory drugs and glioblastoma multiforme. Am J Epidemiol 159:1131-1139
32. Van Hecken A, Schwartz JI, Depre M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40:1109-1120
33. Johannesdottir SA, Chang ET, Mehnert F, Schmidt M, Olesen AB, Sørensen HT (2012) Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer 118:4768-4776
34. Chirasani SR, Leukel P, Gottfried E, Hochrein J, Stadler K, Neumann B, Oefner PJ, Gronwald W, Bogdahn U, Hau P, Kreutz M, Grauer OM (2013) Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model. Int J Cancer 132:843-853
35. Zerbini LF, Tamura RE, Correa RG, Czibere A, Cordeiro J, Bhasin M, Simabuco FM, Wang Y, Gu X, Li L, Sarkar D, Zhou JR, Fisher PB, Libermann TA (2011) Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy. PLoS ONE 6:e24285
36. Ma HI, Chiou SH, Hueng DY, Tai LK, Huang PI, Kao CL, Chen YW, Sytwu HK (2011) Celecoxib and radioresistant glioblastoma-derived CD133 + cells: improvement in radiotherapeutic effects. Laboratory investigation. J Neurosurg 114:651-662
37. Grosch S, Maier TJ, Schiffmann S, Geisslinger G (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98:736-747
38. Crane CH, Mason K, Janjan NA, Milas L (2003) Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am J Clin Oncol 26:S81-S84
39. Kardosh A, Golden EB, Pyrko P, Uddin J, Hofman FM, Chen TC, Louie SG, Petasis NA, Schonthal AH (2008) Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma by bortezomib in combination with celecoxib or its non-coxib analogue, 2, 5-dimethyl-celecoxib. Cancer Res 68:843-851
40. Kang SG, Kim JS, Park K, Kim JS, Groves MD, Nam DH (2006) Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncol Rep 15:7-13
41. Kim CK, Joe YA, Lee SK, Kim EKOE, Kim HK, Oh BJ, Hong SH, Hong YK (2010) Enhancement of anti-tumor activity by low dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model. Cancer Lett 288:251-260
42. Grossman SA, Oslon J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG (2008) Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol 10:190-198